SEARCH

SEARCH BY CITATION

References

  • 1
    Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha IFN: a preliminary report. N Engl J Med 1986; 315: 15751578.
  • 2
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant IFN alpha: a multicenter randomized, controlled trial. N Engl J Med 1989; 321: 15011506.
  • 3
    Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Nishimoto H, Mizuno M, et al. Predictive factors in chronic hepatitis C under IFN treatment [Abstract]. Hepatology 1992; 16: 598.
  • 4
    Yamada G, Takahashi M, Endo H, Doi T, Miyamoto R, Shimomura H, Yamamoto K, et al. Quantitative hepatitis C virus RNA and liver histology in chronic hepatitis C patients treated with IFN alpha. Gut 1993; (Suppl 34): S133S134.
  • 5
    Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 15011505.
  • 6
    Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339: 1543.
  • 7
    Kinoshita M, Hadama T, Katagiri T, Fukui T, Koura M, Oka M, Seno T, et al. The competitive assay for human hepatitis C virus RNA. J Med Tech 1993; 37: 214218 (in Japanese).
  • 8
    Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, et al. Hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673679.
  • 9
    Yamada G, Takahashi M, Tsuji T. Quantitative HCV RNA and effect of interferon therapy in chronic hepatitis C. Dig Dis Sci 1992; 12: 19261927.
  • 10
    Simmonds P, Holmes EC, Cha T-A, Chan SW, McOmish F, Irvine B, Beall E, et al. Classification of hepatitis C into six major genotypes and a series of subtypes by phylogenetic analysis and the NS5 region. J Gen Virol 1993; 74: 23912399.
  • 11
    Fukada S, Ando S, Sanou O, Taniai M, Fuji M, Masaki N, Nakamura K, et al. Simultaneous production of natural human tumor necrosis factor α and β and interferon α from BALL-1 cells stimulated by HVJ. Lymphokine Res 1988; 7: 175184.
  • 12
    Chemello L, Alberti A, Rose K, Simmonds P. Hepatitis C serotype and response to interferon therapy. N Eng J Med 1994; 330: 143.
  • 13
    Yoshioka K, Kakamu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293299.
  • 14
    Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992; 16: 619624.